21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
10.89.Z - Production of other food products, not elsewhere classified
20.42.Z - Manufacture of cosmetics and toilet preparations
20.59.Z - Manufacture of other chemical products, not elsewhere classified
21.10.Z - Manufacture of basic pharmaceutical products
32.50.Z - Production of medical devices, instruments, and products, including dental products
52.10.B - Warehousing and storage of other goods
68.20.Z - Rental and management of own or leased real estate
72.11.Z - Scientific research and development activities
72.19.Z - Scientific research and development activities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | 5,6 | 8 | 5,9 | -27 |
EBITDA | 3,5 | 5,9 | 3,3 | -44,5 |
Short time liabilities | 3,3 | 3,3 | 3,3 | 0,9 |
Equity capital | 34,4 | 36,5 | 38,4 | 5,1 |
Operating profit (EBIT) | 5,6 | 7,9 | 5,5 | -30,7 |
Assets | 38,7 | 40,9 | 42,8 | 4,5 |
Net profit (loss) | 5,6 | 8,1 | 5,9 | -27,8 |
Cash | 2,8 | 4,4 | 3,1 | -29,7 |
Net income from sale | 28,1 | 36,3 | 38,1 | 4,9 |
Liabilities and provisions for liabilities | 4,3 | 4,4 | 4,4 | -0,3 |
Working assets | 14,1 | 17,2 | 19,3 | 12,3 |
Depreciation | -2 | -2 | -2,2 | -9,7 |
% | % | % | p.p. | |
Profitability of capital | 16,1 | 22,2 | 15,3 | -6,9 |
Equity capital to total assets | 88,9 | 89,1 | 89,6 | 0,5 |
Gross profit margin | 19,9 | 22,1 | 15,4 | -6,7 |
EBITDA Margin | 12,6 | 16,2 | 8,6 | -7,6 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 42 | 33 | 32 | -1 |
Current financial liquidity indicator | 4.320490837097168 | 5.206710338592529 | 5.79512357711792 | 0,6 |
Net dept to EBITDA | -0.7903823256492615 | -0.7218723893165588 | -0.9225158095359802 | -0,2 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane